News: PXS Synairgen announces additional positive data from LOXL2 inhibitor programme

March 10 (Reuters) - Synairgen Plc SYNG.L

• Additional positive data in lung fibrosis
• Oral administration of one of the compounds significantly inhibited cross-link formation, reduced fibrosis score and improved lung function
• Successful completion of toxicology studies will enable commencement of phase I clinical trials in h2 this year as planned
• Expect to commence phase I clinical trials of LOXL2 inhibitor during second half of 2017
• Expect to hear outcome of Astrazeneca phase II trial of interferon beta during first half of 2017